143 related articles for article (PubMed ID: 1840347)
21. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
[TBL] [Abstract][Full Text] [Related]
22. Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients.
Pisa P; Stenke L; Bernell P; Hansson M; Hast R
Anticancer Res; 1990; 10(3):817-20. PubMed ID: 2114819
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P
Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207
[TBL] [Abstract][Full Text] [Related]
27. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
29. Beta 2 microglobulin in multiple myeloma.
Alexanian R; Barlogie B; Fritsche H
Am J Hematol; 1985 Dec; 20(4):345-51. PubMed ID: 3907332
[TBL] [Abstract][Full Text] [Related]
30. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
31. Urinary alpha 1- and beta 2-microglobulin in light chain proteinuria.
Honkanen E; Pettersson T; Teppo AM
Clin Nephrol; 1995 Jul; 44(1):22-7. PubMed ID: 7554529
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
34. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
35. [The prognosis of patients with multiple myeloma--the aspect of histological distribution to the renal tissue and serum level of beta 2-MG].
Inoue Y; Suzuki K; Enomoto H; Takemura T; Nakamura K
Rinsho Ketsueki; 1992 Aug; 33(8):1012-6. PubMed ID: 1404855
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
Fleury J; Tortochaux J; Legros M; Cure H; Kwiatkowski F; Ferrière JP; Travade P; Dionet C; Gaillard G; Chassagne J
Bull Cancer; 1994 Jul; 81(7):625-31. PubMed ID: 7742606
[TBL] [Abstract][Full Text] [Related]
37. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
38. Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?
van Dobbenburgh OA; Rodenhuis S; Ockhuizen T; Weltevreden E; Houwen B; Fidler V; Meijer S; Marrink J
Br J Haematol; 1985 Dec; 61(4):611-20. PubMed ID: 3910076
[TBL] [Abstract][Full Text] [Related]
39. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
40. [Serum interleukin-6 in multiple myeloma. II. Relation to activity and stage of disease].
Scudla V; Bacovský J; Budíková M; Srovnalík K; Kubalová D
Vnitr Lek; 1995 Sep; 41(9):599-604. PubMed ID: 7483350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]